Phio Pharmaceuticals Stock Forum

$Phio Pharmaceuticals(PHIO.US)$ Low float, keeping an eye on this.

$Phio Pharmaceuticals(PHIO.US)$
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
Phio Pharmaceuticals (NASDAQ: PHIO) announced the inclusion of the University of Pittsburgh Medical Center (UPMC) Department of Dermatology as a clinical trial site for its Phase 1b study of PH-762, bringing the total to five participating sites. This trial involves adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma and aims to...

$Phio Pharmaceuticals(PHIO.US)$ Phio Pharmaceuticals Corp - Has Approved a Reverse Stock Split of Its Shares of Common Stock at a Ratio of 1-for-9! Will become effective July 5

$Phio Pharmaceuticals(PHIO.US)$ Phio Pharmaceuticals Announces Positive Recommendation From Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
newsfile· 5 mins ago
Intratumoral PH-762 has encouraging safety profile in the initial cohort
Escalation to proceed to next dose concentration

$Phio Pharmaceuticals(PHIO.US)$ Phio Pharmaceuticals Corp Files for Mixed Shelf of up to $100 Mln - SEC Filing

$Phio Pharmaceuticals(PHIO.US)$ Benzinga· 1 min ago
Phio Pharmaceuticals Enters Into Purchase Agreement With TRITON Funds; TRITON To Purchase 18.8% Of Phio's Common Shares Yielding Gross Proceeds Of Up To $621,000

$Phio Pharmaceuticals(PHIO.US)$
NEWS
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study

$Phio Pharmaceuticals(PHIO.US)$
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound.
Preclinical studies demonstrate:
The data, authored by Melissa Maxwell, Lind...

$Phio Pharmaceuticals(PHIO.US)$ Intratumoral Injection of Phio’s Ph-762 Significantly Inhibits Tumor Growth in Murine Tumor Models and May Generate Memory-Specific T Cells